Viewpoint: "Underutilisation of novel antiplatelet agents - Myths, generics, and economics"

Victor L. Serebruany, Seith D. Fortmann

Research output: Contribution to journalArticle

Abstract

Two oral antiplatelet agents have been recently introduced for acute coronary syndromes indication providing alternatives for dual therapy with aspirin and clopidogrel. In fact, worldwide prasugrel has been on the market for four years, and ticagrelor for over two years. Despite declared benefits over clopidogrel, including hypothetical cost saving advantages, in real life, the clinical utilisation of both agents is small. Generic clopidogrel, and price differences are claimed as major obstacles to prevent broader prasugrel and ticagrelor use. However, these economic difficulties are barely supported by available evidence, and served mostly to protect questionable management spending, as an exuse to explain why in reality cardiologists are so sceptical about both novel agents, and to convince the sharehoders that their money is not wasted, misleading the owners with regard to future success. Importantly, brand Plavix® is used worldwide 5-10 times more often than new agents, despite heavy generic competition. The future of prasugrel outside Japan, where much lower reasonable dose will be used is not impressive due to lack of further outcome studies, negative results of the latest trials, and less than four years left before patent expiration. The fate of ticagrelor will depend on verification of deaths numbers in the ongoing United States Department of Justice PLATO investigation, and confirmation of the mortality benefit in the PEGASUS TIMI-54 trial.

Original languageEnglish (US)
Pages (from-to)4-9
Number of pages6
JournalThrombosis and Haemostasis
Volume112
Issue number1
DOIs
StatePublished - May 8 2014

Fingerprint

clopidogrel
Platelet Aggregation Inhibitors
Economics
Social Justice
Acute Coronary Syndrome
Complementary Therapies
Aspirin
Japan
Outcome Assessment (Health Care)
Costs and Cost Analysis
Mortality

Keywords

  • Clinical utilisation
  • Clopidogrel
  • Generics
  • Prasugrel
  • Ticagrelor

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Viewpoint : "Underutilisation of novel antiplatelet agents - Myths, generics, and economics". / Serebruany, Victor L.; Fortmann, Seith D.

In: Thrombosis and Haemostasis, Vol. 112, No. 1, 08.05.2014, p. 4-9.

Research output: Contribution to journalArticle

Serebruany, Victor L. ; Fortmann, Seith D. / Viewpoint : "Underutilisation of novel antiplatelet agents - Myths, generics, and economics". In: Thrombosis and Haemostasis. 2014 ; Vol. 112, No. 1. pp. 4-9.
@article{1dc3ce7eab2c411a93610c417eca42a5,
title = "Viewpoint: {"}Underutilisation of novel antiplatelet agents - Myths, generics, and economics{"}",
abstract = "Two oral antiplatelet agents have been recently introduced for acute coronary syndromes indication providing alternatives for dual therapy with aspirin and clopidogrel. In fact, worldwide prasugrel has been on the market for four years, and ticagrelor for over two years. Despite declared benefits over clopidogrel, including hypothetical cost saving advantages, in real life, the clinical utilisation of both agents is small. Generic clopidogrel, and price differences are claimed as major obstacles to prevent broader prasugrel and ticagrelor use. However, these economic difficulties are barely supported by available evidence, and served mostly to protect questionable management spending, as an exuse to explain why in reality cardiologists are so sceptical about both novel agents, and to convince the sharehoders that their money is not wasted, misleading the owners with regard to future success. Importantly, brand Plavix{\circledR} is used worldwide 5-10 times more often than new agents, despite heavy generic competition. The future of prasugrel outside Japan, where much lower reasonable dose will be used is not impressive due to lack of further outcome studies, negative results of the latest trials, and less than four years left before patent expiration. The fate of ticagrelor will depend on verification of deaths numbers in the ongoing United States Department of Justice PLATO investigation, and confirmation of the mortality benefit in the PEGASUS TIMI-54 trial.",
keywords = "Clinical utilisation, Clopidogrel, Generics, Prasugrel, Ticagrelor",
author = "Serebruany, {Victor L.} and Fortmann, {Seith D.}",
year = "2014",
month = "5",
day = "8",
doi = "10.1160/TH13-10-0862",
language = "English (US)",
volume = "112",
pages = "4--9",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "1",

}

TY - JOUR

T1 - Viewpoint

T2 - "Underutilisation of novel antiplatelet agents - Myths, generics, and economics"

AU - Serebruany, Victor L.

AU - Fortmann, Seith D.

PY - 2014/5/8

Y1 - 2014/5/8

N2 - Two oral antiplatelet agents have been recently introduced for acute coronary syndromes indication providing alternatives for dual therapy with aspirin and clopidogrel. In fact, worldwide prasugrel has been on the market for four years, and ticagrelor for over two years. Despite declared benefits over clopidogrel, including hypothetical cost saving advantages, in real life, the clinical utilisation of both agents is small. Generic clopidogrel, and price differences are claimed as major obstacles to prevent broader prasugrel and ticagrelor use. However, these economic difficulties are barely supported by available evidence, and served mostly to protect questionable management spending, as an exuse to explain why in reality cardiologists are so sceptical about both novel agents, and to convince the sharehoders that their money is not wasted, misleading the owners with regard to future success. Importantly, brand Plavix® is used worldwide 5-10 times more often than new agents, despite heavy generic competition. The future of prasugrel outside Japan, where much lower reasonable dose will be used is not impressive due to lack of further outcome studies, negative results of the latest trials, and less than four years left before patent expiration. The fate of ticagrelor will depend on verification of deaths numbers in the ongoing United States Department of Justice PLATO investigation, and confirmation of the mortality benefit in the PEGASUS TIMI-54 trial.

AB - Two oral antiplatelet agents have been recently introduced for acute coronary syndromes indication providing alternatives for dual therapy with aspirin and clopidogrel. In fact, worldwide prasugrel has been on the market for four years, and ticagrelor for over two years. Despite declared benefits over clopidogrel, including hypothetical cost saving advantages, in real life, the clinical utilisation of both agents is small. Generic clopidogrel, and price differences are claimed as major obstacles to prevent broader prasugrel and ticagrelor use. However, these economic difficulties are barely supported by available evidence, and served mostly to protect questionable management spending, as an exuse to explain why in reality cardiologists are so sceptical about both novel agents, and to convince the sharehoders that their money is not wasted, misleading the owners with regard to future success. Importantly, brand Plavix® is used worldwide 5-10 times more often than new agents, despite heavy generic competition. The future of prasugrel outside Japan, where much lower reasonable dose will be used is not impressive due to lack of further outcome studies, negative results of the latest trials, and less than four years left before patent expiration. The fate of ticagrelor will depend on verification of deaths numbers in the ongoing United States Department of Justice PLATO investigation, and confirmation of the mortality benefit in the PEGASUS TIMI-54 trial.

KW - Clinical utilisation

KW - Clopidogrel

KW - Generics

KW - Prasugrel

KW - Ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=84903795897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903795897&partnerID=8YFLogxK

U2 - 10.1160/TH13-10-0862

DO - 10.1160/TH13-10-0862

M3 - Article

C2 - 24816578

AN - SCOPUS:84903795897

VL - 112

SP - 4

EP - 9

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 1

ER -